2020
DOI: 10.33393/grhta.2020.2130
|View full text |Cite
|
Sign up to set email alerts
|

Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy

Abstract: Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by pain, deformity, instability, reduction of motion and function. It is one of the main causes of disability in older adults, affecting about 10% of men and 18% of women over the age of sixty. There are several Guidelines that support the general clinical decision-making process. However, it is necessary to define an integrated management model for patients with OA to ensure an appropriate and quality healthcare. Methods: … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 11 publications
0
3
0
Order By: Relevance
“…The economic impact of mesotherapy appears to be significant. 36 Ad hoc studies should be designed to measure the impact of drug-sparing effects and avoided drug interactions on economic resources. Treatment algorithms that include mesotherapy could also be evaluated to assess the impact on individual patient care pathways.…”
Section: Health Technology Assessmentmentioning
confidence: 99%
See 1 more Smart Citation
“…The economic impact of mesotherapy appears to be significant. 36 Ad hoc studies should be designed to measure the impact of drug-sparing effects and avoided drug interactions on economic resources. Treatment algorithms that include mesotherapy could also be evaluated to assess the impact on individual patient care pathways.…”
Section: Health Technology Assessmentmentioning
confidence: 99%
“…Treatment algorithms that include mesotherapy could also be evaluated to assess the impact on individual patient care pathways. In fact, existing literature suggests that application of mesotherapy according to good clinical practice 36 seems to be able to satisfy all stakeholders involved.…”
Section: Health Technology Assessmentmentioning
confidence: 99%
“…The healthcare burden related to OA is growing and in many developed countries is considered unsustainable. For example in Spain and Italy-two of the countries with the longest life expectancy in Europe-the average annual cost for OA medications per patient was estimated between €1000 and 1500 per year [5,6]. Globally costs take on an even more impressive aspect.…”
Section: Introductionmentioning
confidence: 99%